ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. (ASPI) launched a primary offering of common stock under an automatic shelf, registering $210,300,405 of shares. The underwriting allocation lists 17,167,380 shares, and the underwriters agreed to purchase at $11.65 per share, yielding approximately $200.0 million in gross proceeds to the company before expenses. Net proceeds are estimated at $199.7 million, with a 30‑day option for up to $31,545,048 of additional shares; if fully exercised, total proceeds before expenses would be about $230.0 million.
The company plans to use proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. ASPI notes recent operating losses and expects existing cash plus the July 2025 raise and this offering to fund operations for more than 12 months from the June 30, 2025 financial statement date. Shares outstanding were 93,406,629 as of October 10, 2025. Underwriter lock-ups apply, and the shares are listed on Nasdaq under “ASPI”.
ASP Isotopes Inc. (ASPI) launched a preliminary prospectus supplement for a primary underwritten offering of common stock on Nasdaq. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are joint bookrunning managers. The underwriters have a 30‑day option to purchase additional shares. Net proceeds are intended for general corporate purposes, including working capital, operating expenses, and capital expenditures, and may also support complementary acquisitions (with no binding commitments).
ASPI’s stock last closed at $13.32 on October 13, 2025. Shares outstanding were 93,406,629 as of October 10, 2025; this is a baseline figure, not the amount being offered. The company reported $67.7 million in cash and cash equivalents as of June 30, 2025, and raised $56.3 million in net proceeds in July 2025. Lock‑ups apply following closing: company 90 days; executive officers 60 days plus 30 days; directors 30 days plus 30 days, subject to stated exceptions.
ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.
Todd Wider, a director of ASP Isotopes Inc. (ASPI), executed equity transactions on 09/14/2025 and 09/15/2025. He acquired 96,000 shares through exercise of stock options with a conversion/exercise price of $2, and the reported ownership following that transaction was 806,230 shares. The filing also reports 21,892 shares withheld to satisfy option exercise-related obligations at an average price of $8.77, and a sale of 74,108 shares on 09/15/2025 at a weighted average price of $8.7551, leaving beneficial ownership of 710,230 shares after the reported transactions.
ASP Isotopes (ASPI) announced a leadership transition. Effective October 1, 2025, founder Paul Mann became Executive Chairman and began a temporary leave from Chief Executive Officer duties for health reasons. The Board appointed Chief Operating Officer Robert Ainscow as Interim CEO (principal executive officer) in addition to his current role.
Mr. Mann will guide strategy and support senior management alongside the Board, while Mr. Ainscow will manage CEO direct reports and external communications. The company made no new employment arrangements for Robert Ainscow. The filing notes Robert is the brother of Donald Ainscow, EVP, General Counsel and Secretary, whose compensation includes a base salary of $425,000 and an initial grant of 400,000 shares vesting over four years.
ASP Isotopes Inc. reported that it has received a purchase order for enriched Barium-137 from a U.S.-based customer. This order relates to the company’s specialized isotope products and reflects commercial demand from a domestic buyer.
The company communicated this development through a press release dated September 30, 2025, which is included as an exhibit to this report for investors seeking additional operational detail.
ASP Isotopes Inc. filed a Form 8-K to report that it issued a press release on September 29, 2025 announcing changes to the executive management teams of ASP Isotopes Inc. and its subsidiary, Quantum Leap Energy LLC, effective October 1, 2025. The press release describing these leadership changes is included as Exhibit 99.1 and incorporated by reference, except for its third through seventh paragraphs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. has extended the deadline to complete its planned acquisition of Renergen Limited, giving more time to meet closing conditions. Under the proposed South African scheme of arrangement, Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The longstop date has been moved from September 30, 2025 to November 28, 2025 to obtain remaining regulatory approval and third-party consents. Implementation of the scheme still depends on approval from the Financial Surveillance Department of the South African Reserve Bank, and both companies continue to work toward timely approval.
Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc. (ASPI), reported multiple transactions on September 8-9, 2025. On 09/08/2025 he executed "sell to cover" sales under a Rule 10b5-1 plan totaling 8,438 shares at a weighted average price of $8.5263 to cover tax withholding from vested restricted stock. On 09/09/2025 he was granted or exercised employee stock options: option grants/exercises include 150,000 options at $0.25, 12,000 options at $2, and 135,000 options at $2, increasing beneficial ownership by option awards to positions listed. Net-share settlements of option exercises resulted in withholding of 4,396, 2,813, and 31,652 shares. After the reported transactions the filing person beneficially owned 1,669,693 shares.